Status:
UNKNOWN
Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer
Lead Sponsor:
Peking University First Hospital
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
To observe and explore the effect of anti-angiogenesis combined with PD-1/PD-L1 therapy in the real world on the survival prognosis of patients with advanced liver cancer, and to summarize the treatme...
Detailed Description
This project is a non-interventional, prospective, multicenter, case follow-up registry management, aiming to observe and explore the effect of anti-angiogenesis combined with PD-1/PD-L1 therapy in th...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age: ≥ 18 years old, male or female;
- Patients diagnosed with advanced liver cancer, including barcelona stage B, C or Chinese liver cancer guidelines stage IIa, IIb, IIIa, IIIb liver cancer patients;
- doctors evaluate patients who can benefit from anti-angiogenesis targeted therapy;
- patients voluntarily join the program and sign informed consent.
- Exclusion criteria:
- The above selection criteria are not met
Exclusion
Key Trial Info
Start Date :
May 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
490 Patients enrolled
Trial Details
Trial ID
NCT05383066
Start Date
May 20 2022
End Date
December 30 2024
Last Update
May 19 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.